Pharmacogenetic and Antidepressant Treatment in Elderly

Centre Hospitalier Universitaire de Besancon28 enrolled

Overview

The study aims to assess the therapeutic benefits of the adaptation of the antidepressant dose to the metabolic capacity (cytochrome P450 2D6) of elderly depressed patients. Therapeutic benefits are evaluated through the enhancement of efficiency, decrease of the action time and the after effects.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Masking

QUADRUPLE

Enrollment

Conditions

Depression

Interventions

urine analysisBIOLOGICAL

a sample of urine is collected during 8 hours.

Eligibility

Sex: ALLMin age: 70 Years

Medical Language ↔ Plain English

Inclusion Criteria: * current major depressive disorder * antidepressant treatment Exclusion Criteria: * dextromethorphan contra-indication * other psychiatric disorder * kidney failure * liver failure mini mental State Examination (MMSE)\<18

Locations (1)

CHU Besancon

Besançon, Doubs, France

Outcomes

Primary Outcomes

patient remission

remission is defined by a Montgomery and asberg depression rating (MADRS) score\<10.

Time frame: 6 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.